Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 17
Hives After CJC-1295 and Ipamorelin
Hives after CJC-1295 and ipamorelin may signal hypersensitivity, but the small human record cannot identify a cause or estimate the risk.
How Many Peptides Is Too Many?
No study defines a safe peptide count after hip replacement. A six-compound mix adds untested interactions and makes adverse effects harder to trace.
MASLD Pharmacotherapy: Clinical Review
A 2026 review frames MASLD drug choice around fibrosis stage and metabolic phenotype, while trials and US labels keep the approved options distinct.
Semaglutide in Two Very Young Children
A two-child case series reports lower BMI-SDS with semaglutide, but no control group and no approval for this preschool age range.
Tirzepatide response over 12 months
A 249-person tirzepatide cohort reported large 12-month losses, but available-case follow-up and nonrandom dosing limit the conclusion.
Apothecary tirzepatide recall explained
FDA records show a 22-vial compounded tirzepatide recall over sterility assurance. Here is what the Class II action does and does not show.
GIP Signaling Across Two Fat Depots
A narrative review finds that GIP effects differ by fat depot and metabolic context, while the human mechanism remains unsettled.
Oral Effects of GLP-1 and GIP Drugs
A 2026 protocol sets out how researchers will map reported oral effects of GLP-1 and dual GLP-1/GIP drugs. It presents no review findings.
GLP-1 Drugs and Reproductive Health
A 2026 review maps contraception, fertility, and pregnancy questions for GLP-1 drugs but does not provide new trial evidence.
Mounjaro access and U.S. biotech rules
A STAT roundup paired a Belgian Mounjaro coverage refusal with a U.S. China-biotech proposal. The two policy stories require separate readings.
Semaglutide and Decision-Making in MDD
A small randomized trial analysis found changes in modeled choice behavior, but it did not show that semaglutide treats depression.
Semaglutide Microneedle Rat Study
A PVA microneedle patch delivered semaglutide and changed weight-related outcomes in rats, with no human efficacy evidence.